- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03653637
Group ("Project Life Force") vs. Individual Suicide Safety Planning RCT (PLF)
Group (Project Life Force) vs. Individual Suicide Safety Planning RCT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Worldwide someone dies by suicide every 40 seconds. In the United States, Veterans exhibit significantly higher suicide risk when compared to the general United States population. One in five suicide deaths is a Veteran and in spite of enhanced suicide prevention services in the Veterans Administration (VA), twenty Veterans commit suicide daily. These very concerning numbers demonstrate an urgent need to develop additional, empirically validated interventions for suicidal Veterans.
One component of the VA's coordinated effort to treat high-risk suicidal Veterans, and diminish suicide risk, is through the construction of a Suicide Safety Plan. Considered a best practice, the SSP instructs one to: recognize personal warning signs of suicide; use internal coping strategies; engage social contacts that can offer support and serve as distraction from suicidal thoughts; contact family members or friends who may help resolve a crisis; provide contact information for VA professionals to help and, specify steps for how to make the immediate environment safer. The patient takes the SSP home for his or her use during (or at the onset of) a suicidal crisis. Safety planning is based on the idea that suicide risk fluctuates over time, and aims to prevent suicidal crises from escalating, and stop individuals from acting on their suicidal thoughts and urges. Research suggests creation of the SSP is effective; one study found that Veterans who present to an emergency room show decreased suicide behavior after creating a SSP.
This study aims to fill this treatment gap by examining a novel intervention integrating skills training with safety planning for high risk suicidal Veterans, "Project Life Force" (PLF). The PLF intervention augments the SSP with skills training, and psychoeducation, to maximize use and effectiveness of the plan in a group setting. This intervention's skill instruction is delivered in a group format. Research suggests groups mitigate loneliness and increase a sense of belonging, which is in line with the extensive literature supporting the interpersonal psychological theory (i.e., that those who die by suicide have a low sense of belonging. More recently, reports on the relation of "military unit cohesion" and suicide risk, suggests that increasing unit cohesion may have a protective effect. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others.
The main objective of this RCT is to examine if Veterans who are at high risk for suicide will benefit from the novel group intervention, PLF, compared to Veterans who receive TAU.The specific aims and hypotheses of PLF are:
Aim 1: To conduct a multi-site randomized clinical trial (RCT) of a group safety planning intervention, "PLF" versus individual safety planning in 265 suicidal Veterans. PLF will be compared with the comparison condition- individual safety planning, the current standard of care, designated as TAU.
Exploratory Aim 2: To test whether increased suicide coping and improved belongingness partially mediates treatment response in PLF>TAU.
Exploratory Aim 3: To test whether group cohesion partially mediates treatment response in PLF.
Exploratory Aim 4: To test whether the change in Safety Plan Quality (post intervention - baseline) is greater PLF>TAU, as well as whether the change in safety plan quality partially mediates treatment response in the follow up period.
Hypothesis A1: Compared to TAU, Veterans who participate in PLF, will demonstrate a decrease in suicidal behavior.
Hypothesis A2: Compared to TAU, Veterans who participate in PLF will show a decrease in depression and hopelessness.
Hypothesis A3: Compared to TAU, Veterans who participate in PLF will have increased compliance and attitudes towards mental health treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
The Bronx, New York, United States, 10468-3904
- James J. Peters VA Medical Center, Bronx, NY
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Discharge from inpatient unit for suicidal ideation or attempts, or placement on the high-risk suicide list maintained by suicide prevention coordinators
- Completion of a safety plan during the past 6 months prior to entry
- Concurrence from the patient's mental health provider for the Veteran to participate in the study and the provider is willing to work with the research team.
Exclusion Criteria:
- Unable to provide informed consent or complete study requirements
- Unable to speak English
- Cognitive difficulties that impair consent capacity
- Unable or unwilling to provide at least one verifiable contact for emergency or tracking purposes
- Unable to attend outpatient group treatment program or tolerate group therapy format
- Active alcohol or opiate dependence requiring medically supervised withdrawal
- Schizophrenia diagnosis
- Participation in another intervention RCT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Project Life Force
A novel, 10-session intervention to enhance currently mandated VA suicide safety planning in a group setting to support its implementation.
PLF is a manualized, weekly 90-minute group treatment lasting 10 weeks coinciding with the time frame for enhanced monitoring of Veterans identified as "high-risk".
Session content is described in Table 1 (see appendix A).
Six of the PLF sessions correspond to a step of the safety plan and teach skills to maximize the use of that particular step of the plan.
The use of emotion regulation skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation, distraction and developing social support in the specific context of implementing a safety plan.
Mindfulness is not covered.
PLF is augmented with additional skill modules on physical health management, education pertaining to suicide risk, promoting positive emotion and suicide prevention mobile apps.
PLF patients also receive usual care.
|
A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal.
The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan.
Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others.
The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
Other Names:
|
|
Active Comparator: Treatment-As-Usual
The comparison condition will be an assessment-only treatment-as-usual (TAU).
Research team will track number of individual mental health appointments, SPC outreach contacts, and usage patterns of safety plans.
Veterans in both randomized conditions will be receiving the mandated monitoring, outreach, and involvement of SPC staff and clinical team management that constitutes standard VA care for suicidal individuals.
|
The comparison condition will be an assessment-only treatment-as-usual (TAU).
Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Columbia Suicide Rating Scale (C-SSRS)
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
Columbia Suicide Rating Scale (C-SSRS) will be used to count prospective or treatment emergent suicidal behaviors. The CSSRS has been used in many treatment trials, and to measure treatment emergent suicidal events during pharmacotherapy. C-SSRS contains a subscale on suicidal ideation which is scored from 1-5; higher numbers indicate increased suicidal thinking. The definition of suicide attempt for the primary outcome will consist of any actual suicide attempt, aborted suicide attempt, or interrupted suicide attempt according to the CSSR-S. |
Baseline, 3 Month, 6 Month, 12 Month
|
|
Suicidal Behavior by Chart Abstraction
Time Frame: 12 Month
|
An independent research assessor who is blinded to study condition will complete all outcome assessments.
Data for all types of suicidal behavior including suicides, suicide attempts, interrupted attempts, aborted attempts, and preparatory behavior for suicide, will be obtained.
The nomenclature and definitions for suicide-related behaviors will follow the Center for Disease Control and Prevention's (CDC) definitions.
Suicidal behavior over the 12-month time frame is a cumulative outcome such that detection of suicidal behavior at any of the outcome points, or by any method, leads to a "positive" indication for the suicidal behavior composite.
|
12 Month
|
|
Death by Suicide by National Death Index Survey Findings
Time Frame: 12 Month
|
At month 42, each site's research assistant will query the site's state vital statistics registry for all individuals on this list.
For all those who are found to be deceased, data will be abstracted pertaining to his/her death and the probability of suicide from the Death Certificate.
The 12-month delay in review is necessary because of the well-known lag in recording deaths in state vital statistics registries.
|
12 Month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Inventory-II Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Beck Depression Inventory-II (BDI-II) measures depressive severity with 21 items on a Likert scale.
It has high internal consistency, construct validity, and test-retest reliability.
Each question has a set of at least four possible answer choices ranging in intensity.
When the test is scored, a value of 0 to 3 is assigned for each answer, and items are summed for a total score (ranging from 0-63).
Higher scores indicate worse depressive severity.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Beck Hopelessness Scale Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Beck Hopelessness Scale (BHS) measures hopelessness with 20 binary (true/false) items.
Items are recoded so that optimistic beliefs equal 0 and pessimistic beliefs equal 1. Recoded items are summed for a total score (ranging from 0-20), and higher scores indicate more severe hopelessness.
The BHS demonstrates excellent internal reliability and external validity.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Suicide-related Coping Scale Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Suicide-Related Coping Scale (SRCS) has 17 items assessing suicide-related coping (knowledge of, and perceived confidence in, using internal coping strategies and external supports to regulate suicidal thoughts and urges).
Items are rated on a 5-point scale (Strongly disagree (0) - Strongly agree (4)).
All items are summed for a total score (range 0-68), and the first 14 items can also be used for "external coping" and "internal coping" subscales (7 items each; total range 0-28).
Higher scores show improved suicide-related coping.
The SRCS has acceptable internal and external validity.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Outpatient Mental Health Treatment Utilization
Time Frame: 12 Month
|
Outpatient Mental Health Treatment Utilization was quantified using CPRS.
The number of outpatient non-PLF mental health visits from the past three months was counted.
|
12 Month
|
|
Drug Abuse Screening Test 10 (DAST-10)
Time Frame: 12 Month
|
The DAST-10 measures drug use over the past twelve months to identify potential drug use disorder with 10 binary items (0/1).
Total scores range from 0 to 10. Scores of 0 indicate no problems, 1-2 low-level, 3-5 moderate level, 6-8 substantial level, and 9-10 severe level.
|
12 Month
|
|
Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)
Time Frame: 12 Month
|
The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief 3-item alcohol screening tool used to identify individuals who may be at risk for hazardous drinking or have an alcohol use disorder.
Each item is rated from 0 to 4, and total scores range from 0 - 12. Higher scores indicated an increased likelihood that an individual's drinking is endangering his or her safety.
|
12 Month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Group Cohesion Scale-Revised Change
Time Frame: Weeks 1, 5, 10
|
Group cohesion will be measured by the The Group Cohesion Scale-Revised, a 25-item self-report measure that assesses aspects of group cohesion including communication, interaction, member retention, decision making, vulnerability among group members and consistency between group and individual goals with a four-point scale.
This scale will be used for participants randomized to the PLF treatment at 3 times points before a group session.
The scale demonstrated high validity and reliability in research settings and was found to be sensitive to change in a psychodrama group treatment.
|
Weeks 1, 5, 10
|
|
Ohio State University Traumatic Brain Injury Identification Method
Time Frame: Baseline
|
The Ohio State University Traumatic Brain Injury Identification Method is a standardized, 3-5-minute structured interview designed elicit a person's lifetime history of TBI.
|
Baseline
|
|
Mini Mental State Exam
Time Frame: Baseline
|
The Mini Mental State Exam is a questionnaire used to measure cognitive impairment.
This scale has good validity and construct validity and will be used to examine if participants are cognitively able to participate in the study.
|
Baseline
|
|
Interpersonal Needs Questionnaire Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Interpersonal Needs Questionnaire-15 (INQ-15) consists of 15 items assessing thwarted interpersonal needs along two domains: Thwarted Belongingness (TB, nine items) and Perceived Burdensomeness (PB, six items).
All items are rated from one (not at all true for me) to seven (very true for me).
Six items from the TB subscale are reverse-keyed and reverse-scored.
Items are summed for total scores (TB total score range: 9-63 and PB score range: 6-42).
Higher scores indicate increased severity of TB and PB.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Buss-Perry Aggression Questionnaire Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Buss-Perry Aggression Questionnaire (BPAQ) assesses aggression in four domains (anger, hostility, physical aggression, and verbal aggression) with 29 items on a 4-point scale (Extremely uncharacteristic (0) - Extremely characteristic (3)).
Items in each domain are summed for domain scores, and higher scores indicate more aggression severity in the respective domain.
Total score ranges are: anger: 7-35, hostility: 8-40, physical aggression: 9-45, verbal aggression: 5-25.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Insomnia Severity Index Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Insomnia Severity Index (ISI) is a 7-item brief screening measure of insomnia.
Items include insomnia severity (falling asleep, staying asleep, and waking too early), satisfaction with sleep, the extent to which sleep difficulties impair daily functioning, how noticeable low quality of life due to sleep difficulties is to others, and distress about sleep difficulties.
Item responses range from 0 - 4 and are summed for total scores (range 0-28).
Higher scores indicate more severe insomnia.
The ISI has good internal consistency and validity for treatment research.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Beck Lethality Scale Change
Time Frame: 12 Month
|
The Beck Lethality Scale (BLS) is an interview-administered measure of medical lethality of a suicide attempt for eight possible methods (i.e., coma-producing drugs, non-coma-producing drugs, shooting, burning, drowning, cutting, jumping, and hanging).
The BLS was used following suicidal behavior over the full study duration.
Each item (i.e., each method) is rated from "0" (none or minimal damage) to "10" (death) based on an examination of the patient's physical condition on admission, review of the medical charts, and consultation with the attending physician.
Higher scores on each method indicate higher lethality for that method.
The highest lethality rating across all of the eight methods (none or minimal damage to death) was used as a total score.
|
12 Month
|
|
Beck Suicide Intent Scale Change
Time Frame: Baseline, 3 Month, 6 Month, 12 Month
|
The Suicide Intent Scale (SIS) measures the retrospective intensity of the wish to die at the time of a suicide attempt with 20 items.
Each item is graded in intensity from 0 to 2, and the first 15 items are summed for a total score (ranging from 0 to 30).
Higher scores indicate higher suicide intent.
The SIS has high inter-rater reliability and internal consistency.
|
Baseline, 3 Month, 6 Month, 12 Month
|
|
Mini International Neuropsychiatric Interview
Time Frame: Baseline
|
The Mini International Neuropsychiatric Interview (MINI) is a structured diagnostic interview that assesses the presence of psychiatric disorders according to DSM-IV or ICD-10 criteria, with good interrater and test-retest reliability.
The MINI was used to determine psychiatric diagnoses (lifetime and current).
|
Baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marianne S. Goodman, MD, James J. Peters Veterans Affairs Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MHBB-025-17F
- 1I01CX001705-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.